Overview

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, maximum tolerated dose, and overall response rate of tivozanib (AV-951) and paclitaxel in a breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

AVEO Pharmaceuticals, Inc.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel